Interview with the Innovators

Dr Neal Shore discusses the importance of PSMA PET imaging across a range of PSA values and how PYLARIFY® (piflufolastat F 18) will affect imaging of patients with oligometastatic prostate cancer.

Dr Neal Shore elaborates on the ability of PYLARIFY® (piflufolastat F 18) to detect metastases and the practical aspects of next-generation imaging.

Dr Neal Shore discusses the rationale of prostate-specific membrane antigen (PSMA) PET/CT to guide prostate cancer treatment.

Combinations of agents have replaced sunitinib as first-line therapy for advanced renal-cell cancer. Laura Wood, RN, MSN, OCN; Megan Price, MSN, APRN, FNP-C; and Virginia Seery, MSN, RN, ANP-BC, AOCNP, discuss their best practices for helping patients get the most benefit out of combination therapy for their advanced renal-cell cancer diagnosis.

Dr Neal Shore introduces the current global landscape of various imaging modalities for prostate cancer, including a new prostate-specific membrane antigen (PSMA)-targeted PET/CT agent, PYLARIFY^® (piflufolastat F 18).

Laura Wood, RN, MSN, OCN; Megan Price, MSN, APRN, FNP-C; and Virginia Seery, MSN, RN, ANP-BC, AOCNP, discuss strategies for addressing patients’ concerns about how combination therapy may impact their activities of daily living and quality of life.

The last 10 to 15 years has seen important advances in the management of advanced renal-cell cancer. Laura Wood, RN, MSN, OCN; Megan Price, MSN, APRN, FNP-C; and Virginia Seery, MSN, RN, ANP-BC, AOCNP, discuss how real-world efficacy and safety data influence the conversations they have with their patients with advanced renal-cell carcinoma regarding treatment options.

Megan Price, MSN, APRN, FNP-C, and Virginia Seery, MSN, RN, ANP-BC, AOCNP, discuss their approach to conversations with patients and families regarding first-line therapy for advanced renal-cell carcinoma. They also describe what resources they share with patients to help them after the initial consultation.

Maintaining quality of life for cancer patients means different things to different cancer patients. However, the conversation starts with helping patients manage their expectations regarding their therapy and how it will impact their quality of life. Please join Laura Wood, RN, MSN, OCN, Megan Price, MSN, APRN, FNP-C, and Virginia Seery, MSN, RN, ANP-BC, AOCNP, as they examine the many ways that they collaborate with their oncology team colleagues to assess and review how an individual patient’s treatment regimen is influencing that patient’s quality of life.